160 related articles for article (PubMed ID: 38091664)
1. Clinical and immunological benefits of full primary COVID-19 vaccination in individuals with SARS-CoV-2 breakthrough infections: A prospective cohort study in non-hospitalized adults.
Prelog M; Jeske SD; Asam C; Fuchs A; Wieser A; Gall C; Wytopil M; Mueller-Schmucker SM; Beileke S; Goekkaya M; Kling E; Geldmacher C; Rubio-Acero R; Plank M; Christa C; Willmann A; Vu M; Einhauser S; Weps M; Lampl BMJ; Almanzar G; Kousha K; Schwägerl V; Liebl B; Weber B; Drescher J; Scheidt J; Gefeller O; Messmann H; Protzer U; Liese J; Hoelscher M; Wagner R; Überla K; Steininger P;
J Clin Virol; 2024 Feb; 170():105622. PubMed ID: 38091664
[TBL] [Abstract][Full Text] [Related]
2. Humoral and cellular immune responses in fully vaccinated individuals with or without SARS-CoV-2 breakthrough infection: Results from the CoV-ADAPT cohort.
Hollstein MM; Dierks S; Schön MP; Bergmann A; Abratis A; Eidizadeh A; Kaltenbach S; Schanz J; Groß U; Leha A; Kröger A; Andag R; Zautner AE; Fischer A; Erpenbeck L; Schnelle M
J Med Virol; 2023 Oct; 95(10):e29122. PubMed ID: 37787583
[TBL] [Abstract][Full Text] [Related]
3. Vaccination and Omicron BA.1/BA.2 Convalescence Enhance Systemic but Not Mucosal Immunity against BA.4/5.
Diem G; Jäger M; Dichtl S; Bauer A; Lass-Flörl C; Reindl M; Wilflingseder D; Posch W
Microbiol Spectr; 2023 Jun; 11(3):e0516322. PubMed ID: 37098903
[TBL] [Abstract][Full Text] [Related]
4. Wild-type SARS-CoV-2 neutralizing immunity decreases across variants and over time but correlates well with diagnostic testing.
O'Shea KM; Schuler CF; Chen J; Troost JP; Wong PT; Chen K; O'Shea DR; Peng W; Gherasim C; Manthei DM; Valdez R; Baldwin JL; Baker JR
Front Immunol; 2023; 14():1055429. PubMed ID: 36845123
[TBL] [Abstract][Full Text] [Related]
5. Eleven-month longitudinal study of antibodies in SARS-CoV-2 exposed and naïve primary health care workers upon COVID-19 vaccination.
Dobaño C; Ramírez-Morros A; Alonso S; Ruiz-Olalla G; Rubio R; Vidal M; Prados de la Torre E; Jairoce C; Mitchell RA; Barrios D; Jiménez A; Rodrigo Melero N; Carolis C; Izquierdo L; Zanoncello J; Aguilar R; Vidal-Alaball J; Moncunill G; Ruiz-Comellas A
Immunology; 2022 Dec; 167(4):528-543. PubMed ID: 36065677
[TBL] [Abstract][Full Text] [Related]
6. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
[TBL] [Abstract][Full Text] [Related]
7. Determinants of early antibody responses to COVID-19 mRNA vaccines in a cohort of exposed and naïve healthcare workers.
Moncunill G; Aguilar R; Ribes M; Ortega N; Rubio R; Salmerón G; Molina MJ; Vidal M; Barrios D; Mitchell RA; Jiménez A; Castellana C; Hernández-Luis P; Rodó P; Méndez S; Llupià A; Puyol L; Rodrigo Melero N; Carolis C; Mayor A; Izquierdo L; Varela P; Trilla A; Vilella A; Barroso S; Angulo A; Engel P; Tortajada M; García-Basteiro AL; Dobaño C
EBioMedicine; 2022 Jan; 75():103805. PubMed ID: 35032961
[TBL] [Abstract][Full Text] [Related]
8. Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine breakthrough infections: a multicentre cohort study.
Chia PY; Ong SWX; Chiew CJ; Ang LW; Chavatte JM; Mak TM; Cui L; Kalimuddin S; Chia WN; Tan CW; Chai LYA; Tan SY; Zheng S; Lin RTP; Wang L; Leo YS; Lee VJ; Lye DC; Young BE
Clin Microbiol Infect; 2022 Apr; 28(4):612.e1-612.e7. PubMed ID: 34826623
[TBL] [Abstract][Full Text] [Related]
9. BNT162b2 COVID-19 vaccine and correlates of humoral immune responses and dynamics: a prospective, single-centre, longitudinal cohort study in health-care workers.
Lustig Y; Sapir E; Regev-Yochay G; Cohen C; Fluss R; Olmer L; Indenbaum V; Mandelboim M; Doolman R; Amit S; Mendelson E; Ziv A; Huppert A; Rubin C; Freedman L; Kreiss Y
Lancet Respir Med; 2021 Sep; 9(9):999-1009. PubMed ID: 34224675
[TBL] [Abstract][Full Text] [Related]
10. Are SARS-CoV-2 Antibodies Detectable in Human Milk After Vaccination Against COVID-19?
Scaggs Huang F
J Pediatric Infect Dis Soc; 2022 Apr; 11(4):126. PubMed ID: 35394545
[TBL] [Abstract][Full Text] [Related]
11. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 S1 Subunit Booster Vaccination Elicits Robust Humoral Immune Responses in Aged Mice.
Kim E; Khan MS; Ferrari A; Huang S; Sammartino JC; Percivalle E; Kenniston TW; Cassaniti I; Baldanti F; Gambotto A
Microbiol Spectr; 2023 Jun; 11(3):e0436322. PubMed ID: 37162333
[TBL] [Abstract][Full Text] [Related]
13. Shift in SARS-CoV-2 variants of concern from Delta to Omicron was associated with reduced hospitalizations, increased risk of breakthrough infections but lesser disease severity.
Mwendwa F; Kanji A; Bukhari AR; Khan U; Sadiqa A; Mushtaq Z; Nasir N; Mahmood SF; Aamir UB; Hasan Z
J Infect Public Health; 2024 Jun; 17(6):1100-1107. PubMed ID: 38714122
[TBL] [Abstract][Full Text] [Related]
14. Characterizing Longitudinal Antibody Responses in Recovered Individuals Following COVID-19 Infection and Single-Dose Vaccination: A Prospective Cohort Study.
Olmstead AD; Nikiforuk AM; Schwartz S; Márquez AC; Valadbeigy T; Flores E; Saran M; Goldfarb DM; Hayden A; Masud S; Russell SL; Prystajecky N; Jassem AN; Morshed M; Sekirov I
Viruses; 2022 Oct; 14(11):. PubMed ID: 36366515
[TBL] [Abstract][Full Text] [Related]
15. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
16. Quantitative Analysis of SARS-CoV-2 Antibody Levels in Cancer Patients Post Three Doses of Immunization and Prior to Breakthrough COVID-19 Infections.
Macrae K; Martinez-Cajas J; Bessai K; Abdulhamed A; Gong Y
Curr Oncol; 2022 Sep; 29(10):7059-7071. PubMed ID: 36290831
[TBL] [Abstract][Full Text] [Related]
17. A case report of breakthrough infection with the SARS-CoV-2 delta variant and household transmission: Role of vaccination, anti-spike IgG and neutralizing activity.
Moriyama Y; Ishikane M; Ueno M; Matsunaga A; Ishizaka Y; Arashiro T; Kanno T; Suzuki T; Kimura K
J Infect Chemother; 2022 Jul; 28(7):962-964. PubMed ID: 35461768
[TBL] [Abstract][Full Text] [Related]
18. Community transmission and viral load kinetics of the SARS-CoV-2 delta (B.1.617.2) variant in vaccinated and unvaccinated individuals in the UK: a prospective, longitudinal, cohort study.
Singanayagam A; Hakki S; Dunning J; Madon KJ; Crone MA; Koycheva A; Derqui-Fernandez N; Barnett JL; Whitfield MG; Varro R; Charlett A; Kundu R; Fenn J; Cutajar J; Quinn V; Conibear E; Barclay W; Freemont PS; Taylor GP; Ahmad S; Zambon M; Ferguson NM; Lalvani A;
Lancet Infect Dis; 2022 Feb; 22(2):183-195. PubMed ID: 34756186
[TBL] [Abstract][Full Text] [Related]
19. Longitudinal Study after Sputnik V Vaccination Shows Durable SARS-CoV-2 Neutralizing Antibodies and Reduced Viral Variant Escape to Neutralization over Time.
Gonzalez Lopez Ledesma MM; Sanchez L; Ojeda DS; Oviedo Rouco S; Rossi AH; Varese A; Mazzitelli I; Pascuale CA; Miglietta EA; Rodríguez PE; Pallarés HM; Costa Navarro GS; Caramelo JJ; Rothlauf PW; Liu Z; Bloyet LM; Cornejo Pontelli M; Rasetto NB; Wenker SD; Ramis LY; Bialer MG; de Leone MJ; Hernando CE; Bianchimano L; Ríos AS; Treffinger Cienfuegos MS; Rodriguez García DR; Longueira Y; Laufer N; Alvarez D; Ceballos A; Ochoa V; Monzani C; Turk G; Salvatori M; Carradori J; Prost K; Rima A; Varela C; Ercole R; Toro RI; Gutierrez S; Zubieta M; Acuña D; Nabaes Jodar MS; Torres C; Mojsiejczuk L; Viegas M; Velazquez P; Testa C; Kreplak N; Yanovsky M; Whelan S; Geffner J; Pifano M; Gamarnik AV
mBio; 2022 Feb; 13(1):e0344221. PubMed ID: 35073758
[TBL] [Abstract][Full Text] [Related]
20. Kinetics and Persistence of the Cellular and Humoral Immune Responses to BNT162b2 mRNA Vaccine in SARS-CoV-2-Naive and -Experienced Subjects: Impact of Booster Dose and Breakthrough Infections.
Desmecht S; Tashkeev A; El Moussaoui M; Marechal N; Perée H; Tokunaga Y; Fombellida-Lopez C; Polese B; Legrand C; Wéry M; Mni M; Fouillien N; Toussaint F; Gillet L; Bureau F; Lutteri L; Hayette MP; Moutschen M; Meuris C; Vermeersch P; Desmecht D; Rahmouni S; Darcis G
Front Immunol; 2022; 13():863554. PubMed ID: 35711445
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
